Dll1 has also been implicated in promoting tumor initiating cells/cancer stem cells in multiple cancers such as glioblastoma, renal cell carcinoma, and rhabdomyosarcoma [29–31] and enhancing T-cell-mediated antitumor immunity [32]. Here, DLL1 is linked to renal cell carcinoma.